This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fedorov, L. M. Articles by Rapp, U. R. Search for Related Content PubMed PubMed Citation Articles by Fedorov, L. M. Articles by Rapp, U. R.

Loss of p53 in craf-induced Transgenic Lung Adenoma Leads to Tumor Acceleration and Phenotypic Switch^{1 ,,2}

Institut für Medizinische Strahlenkunde und Zellforschung (MSZ), Bayerische Julius-Maximilians-Universität, D-97078 Würzburg [L. M. F., O. Y. T., T. T., R. G., U. R. R.], and Pathologisches Institut Histologisches Labor, Friedrich-Alexander-Universität Erlangen-Nürnberg, D-91054 Erlangen [T. P.], Germany

One of the most frequent malignancies in humans is lung adenocarcinoma.To develop novel diagnostic and therapeutic approaches for the management of this disease, animal models are required. We have used transgenic mice with lung-targeted expression of the CRaf kinase to evaluate genes altered frequently in human lung adenocarcinoma for their effect on tumor progression. Here we report that loss of p53 dramatically accelerates tumor development and induces a phenotypic switch in the target cell from cuboid to a nonciliated columnar morphology. Coexpression of lung epithelial cell markers surfactant protein C and Clara cell antigen suggests that tumor cell dedifferentiation could be involved in this process. The effect of p53 is specific, because loss of one of its target genes, p21^CIP1/WAF1, did not have this effect on cell phenotype although tumor latency was also reduced significantly. Neither loss of p53 nor p21 stimulated acquisition of the metastasis program beyond the stage of bronchiolar extension. This mouse model for pulmonary adenoma and adenocarcinoma should be very helpful for a better understanding of pathogenesis and treatment of this most deadly human cancer.

This article has been cited by other articles:

				A. Yu. Nikitin, A. Alcaraz, M. R. Anver, R. T. Bronson, R. D. Cardiff, D. Dixon, A. E. Fraire, E. W. Gabrielson, W. T. Gunning, D. C. Haines, et al. Classification of Proliferative Pulmonary Lesions of the Mouse: Recommendations of the Mouse Models of Human Cancers Consortium Cancer Res., April 1, 2004; 64(7): 2307 - 2316. [Abstract] [Full Text] [PDF]

				O. J. Finn Premalignant Lesions as Targets for Cancer Vaccines J. Exp. Med., December 1, 2003; 198(11): 1623 - 1626. [Full Text] [PDF]